<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Imunon Inc — News on 6ix</title>
    <link>https://6ix.com/company/imunon-inc</link>
    <description>Latest news and press releases for Imunon Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/imunon-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835838278dffbe2df0fcb9b.webp</url>
      <title>Imunon Inc</title>
      <link>https://6ix.com/company/imunon-inc</link>
    </image>
    <item>
      <title>IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-reports-2025-financial-results-and-provides-business-update-highlighting-significant-progress-with-pivotal-phase-3-study</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-reports-2025-financial-results-and-provides-business-update-highlighting-significant-progress-with-pivotal-phase-3-study</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with</description>
    </item>
    <item>
      <title>IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-reports-updated-phase-2-data-showing-continued-improvement-in-median-overall-survival-with-imnn-001-in-women-with-newly-diagnosed-advanced-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-reports-updated-phase-2-data-showing-continued-improvement-in-median-overall-survival-with-imnn-001-in-women-with-newly-diagnosed-advanced-ovarian-cancer</guid>
      <pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
      <description>The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months</description>
    </item>
    <item>
      <title>IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated</description>
    </item>
    <item>
      <title>IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-sharpens-focus-promising-pivotal-130500924</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-sharpens-focus-promising-pivotal-130500924</guid>
      <pubDate>Thu, 05 Feb 2026 13:05:00 GMT</pubDate>
      <description>Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strat</description>
    </item>
    <item>
      <title>IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-announces-pricing-7-0-133000389</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-announces-pricing-7-0-133000389</guid>
      <pubDate>Tue, 30 Dec 2025 13:30:00 GMT</pubDate>
      <description>LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock, in a re</description>
    </item>
    <item>
      <title>IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-2025-transformative-significant-clinical-161000525</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-2025-transformative-significant-clinical-161000525</guid>
      <pubDate>Mon, 29 Dec 2025 16:10:00 GMT</pubDate>
      <description>Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001&apos;s Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust dat</description>
    </item>
    <item>
      <title>IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-reports-third-quarter-2025-124500558</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-reports-third-quarter-2025-124500558</guid>
      <pubDate>Thu, 13 Nov 2025 12:45:00 GMT</pubDate>
      <description>R&amp;D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and</description>
    </item>
    <item>
      <title>IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-public-webcast-highlights-resilience-183000254</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-public-webcast-highlights-resilience-183000254</guid>
      <pubDate>Mon, 10 Nov 2025 18:30:00 GMT</pubDate>
      <description>Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today hosted a compelling public webcast, where cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 minimal residual disease (MRD) trials, clinicians, statistical experts and IMUNON executives shared critical insights into the disease and</description>
    </item>
    <item>
      <title>IMUNON R&amp;D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-r-d-day-showcases-123000181</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-r-d-day-showcases-123000181</guid>
      <pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
      <description>Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women’s health are encouraged to attend, either In-person or virtually LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated i</description>
    </item>
    <item>
      <title>IMUNON R&amp;D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-r-d-day-opportunity-130500076</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-r-d-day-opportunity-130500076</guid>
      <pubDate>Fri, 07 Nov 2025 13:05:00 GMT</pubDate>
      <description>Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&amp;D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring in-depth discussions with experts including principal investigators leading the Phase 3 OVATION 3 clinica</description>
    </item>
    <item>
      <title>IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-hold-third-quarter-2025-130500957</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-hold-third-quarter-2025-130500957</guid>
      <pubDate>Thu, 06 Nov 2025 13:05:00 GMT</pubDate>
      <description>LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025 to discuss financial results for the third quarter ended September 30, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. To participate in the</description>
    </item>
    <item>
      <title>IMUNON Announces Webcast of In-Person R&amp;D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-announces-webcast-person-r-130500290</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-announces-webcast-person-r-130500290</guid>
      <pubDate>Tue, 04 Nov 2025 13:05:00 GMT</pubDate>
      <description>Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators, oncology and statistical experts LAWRENCEVILLE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will host an R&amp;D Day fo</description>
    </item>
    <item>
      <title>IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-present-phase-3-ovation-120000519</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-present-phase-3-ovation-120000519</guid>
      <pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
      <description>Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women</description>
    </item>
    <item>
      <title>IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-present-translational-data-phase-140100939</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-present-translational-data-phase-140100939</guid>
      <pubDate>Thu, 23 Oct 2025 14:01:00 GMT</pubDate>
      <description>IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new translational data from the Phase 2 OVATION 2 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, will be presented at the Society for Immunothe</description>
    </item>
    <item>
      <title>IMUNON Hosts R&amp;D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-hosts-randd-day-highlighting-progress-on-ovation-3-study-in-pursuit-of-first-frontline-immunotherapy-for-advanced-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-hosts-randd-day-highlighting-progress-on-ovation-3-study-in-pursuit-of-first-frontline-immunotherapy-for-advanced-ovarian-cancer</guid>
      <pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
      <description>Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from</description>
    </item>
    <item>
      <title>IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-invited-present-placcine-dna-121000411</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-invited-present-placcine-dna-121000411</guid>
      <pubDate>Fri, 17 Oct 2025 12:10:00 GMT</pubDate>
      <description>Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform’s potential as a next-generation vaccine, today announced that members of its leadership team will deliver oral presentations highlighting IMNN-101, its investigational DNA plasmid vaccine based on the Company’s pro</description>
    </item>
    <item>
      <title>IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-present-phase-3-ovarian-122000517</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-present-phase-3-ovarian-122000517</guid>
      <pubDate>Tue, 14 Oct 2025 12:20:00 GMT</pubDate>
      <description>Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established plans to accelerate patient recruitment LAWRENCEVILLE, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a trials-in-progress abstract on the ongoing Phase</description>
    </item>
    <item>
      <title>IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment…</title>
      <link>https://6ix.com/company/imunon-inc/news/imnn-ovation-2-translational-data-shows-imnn-001-alters-tumor-microenvironment</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imnn-ovation-2-translational-data-shows-imnn-001-alters-tumor-microenvironment</guid>
      <pubDate>Tue, 23 Sep 2025 13:36:00 GMT</pubDate>
      <description>By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Translational Data from OVATION 2 Trial Presented at AACR Special Conference On September 22, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that new translational data from the Phase 2 OVATION 2 trial of IMNN-001 was presented at the American Association for Cancer Research (AACR) Special Conference in Cancer</description>
    </item>
    <item>
      <title>IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-presents-imnn-001-phase-120500837</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-presents-imnn-001-phase-120500837</guid>
      <pubDate>Mon, 22 Sep 2025 12:05:00 GMT</pubDate>
      <description>Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial sites activated to date and on plan for site expansion to accelerate patient recruitment LAWRENCEVILLE, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, to</description>
    </item>
    <item>
      <title>IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research</title>
      <link>https://6ix.com/company/imunon-inc/news/imunon-present-translational-data-imnn-120500882</link>
      <guid isPermaLink="true">https://6ix.com/company/imunon-inc/news/imunon-present-translational-data-imnn-120500882</guid>
      <pubDate>Fri, 19 Sep 2025 12:05:00 GMT</pubDate>
      <description>OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, will be presented at the American Asso</description>
    </item>
  </channel>
</rss>